NCT06934616

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors

A Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/ VEGF Antibody GB268 in Participants With Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 330 (estimated)
• Sponsor: Genor Biopharma Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors. The study will consist of a dose-escalation stage and an dose-expansion stage.

Conditions

• Solid Tumor Cancer

Interventions

Type	Name	Description
DRUG	GB268	GB268 will be administered via intravenous infusion once every 3 weeks on Days 1 of each 21-day cycle

Timeline

• Start date: 2025-04-24
• Primary completion: 2027-03-01
• Completion: 2028-03-01
• First posted: 2025-04-18
• Last updated: 2025-04-30